权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

ISC-4 as a Novel Lung Cancer Chemopreventive Agent

ISC-4 作为新型肺癌化学预防剂

基本信息

批准号：
7940968
负责人：
ARUN K SHARMA
金额：
$ 7.63万
依托单位：
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-09-30 至 2011-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7940968
关键词：
A/J Mouse ADME Study Accounting Adverse effects Antineoplastic Agents Apoptosis Beta Carotene Biodistribution Biological Factors Biological Models Butanones Cancer Model Carcinogenesis Inhibition Carcinogens Cell Cycle Arrest Cell Cycle Progression Cell Proliferation Cessation of life Chemoprevention Chemopreventive Agent Clinical Trials DNA Adducts Development Dose Effectiveness Enzymes Evaluation Exhibits Goals Health Human Incidence Investigation Isothiocyanates Isotretinoin Laboratories Lead Liver Lung Lung Neoplasms Malignant Neoplasms Malignant neoplasm of lung Metabolism Modification Organ Pharmaceutical Preparations Phase Prevention Prevention strategy Preventive Preventive Intervention Research Safety Selenium Series Signal Pathway Smoker Smoking Prevention Staging Structure Sulfur Testing Time Tobacco use Tobacco-Associated Carcinogen Tocopherols Toxic effect United States Validation Work analog base cancer cell carcinogenesis cell growth design efficacy testing enzyme activity feeding high risk in vivo insight lung cancer prevention melanoma metabolic abnormality assessment mortality novel preclinical study prevent radioactivity analysis research study smoking cessation tool treatment strategy tumor tumor growth

项目摘要

DESCRIPTION (provided by applicant): Lung cancer remains a major health problem for smokers who account for ~90% of the total cases. Despite the identification of several preventive agents and strategies, optimal prevention of lung cancer has not been achieved. More effective agents are therefore required that would safely achieve prevention without drastic side effects. Novel compounds which are rational modifications of natural products and follow a similar mechanism of action, but with enhanced potency, reduced toxicity, and lower dose requirement, may be clinically more relevant. Recently, our extensive structure-activity study involving naturally occurring and synthetic isothiocyanates and corresponding newly developed selenium analogs, the isoselenocyanates, have identified phenylbutyl isoselenocyanate (ISC-4; Ph-(CH2)4-N=C=Se) as the most efficacious anti-cancer agent. ISC-4 was found to be more effective than all other sulfur and selenium analogs studied, including corresponding phenylbutyl isothiocyanate (PBITC; [Ph-(CH2)4-N=C=S]), in inhibiting cell growth in various cancer cells, inducing apoptosis and cell cycle arrest, and inhibiting cell proliferation. It effectively inhibited PI3K/Akt signaling pathway and reduced melanoma tumor growth, by about 60%, without any systemic toxicity, at 0.76 5M dose at which PBITC did not show any reduction in tumor size. Our hypothesis is that ISC-4 retains mechanistic aspects of ITCs action (inhibit Phase I and induce Phase II enzymes; block cell-cycle progression and induce apoptosis) and include added chemopreventive effects of selenium, resulting in a potent yet safe drug for lung cancer prevention. Our preliminary studies supported our hypothesis and have shown ISC-4 to be a promising lung cancer chemopreventive agent. It significantly inhibited CYP450 enzyme activity, induced expression and activity of Phase II enzymes, and substantially reduced formation of pyridoxobutyl (pob)-DNA adducts in A/J mice. The goal of this study is to evaluate this rationally designed agent against NNK (a tobacco carcinogen) induced carcinogenesis and to understand if this activity is due to ISC-4 or one of its active metabolites. The objective of this proposal is to validate the efficacy of ISC-4 for inhibiting NNK induced lung cancer development. The specific aims to test our hypothesis and to accomplish the objectives of this application are (1) To determine the chemopreventive efficacy of ISC-4 in the A/J mouse lung cancer model, and (2) To determine the efficiency at which orally administered ISC-4 or its metabolites reach the target organ (lung) in A/J mice. We will use the experimental approach of evaluating effectiveness of dietary ISC-4 for inhibiting tumor development in A/J mice fed orally with NNK, and carry out the biodistribution study in A/J mice using [14C] ISC-4 to determine if ISC-4 or its metabolites reach the lung. These studies will begin establishing the potential of ISC-4 as lung cancer preventive agent. Long term, validation of ISC-4 as an effective and safe chemopreventive agent would reduce the chances of developing lung cancer in smokers/former smokers thereby directly decreasing the mortality incidence.

描述（由申请人提供）：

项目成果

期刊论文数量（5）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Synthesis and biological evaluation of a novel class of isatin analogs as dual inhibitors of tubulin polymerization and Akt pathway.

DOI：
10.1016/j.bmc.2011.08.044
发表时间：
2011-10-15
期刊：
BIOORGANIC & MEDICINAL CHEMISTRY
影响因子：
3.5
作者：
Krishnegowda, Gowdahalli;Gowda, A. S. Prakasha;Tagaram, Hephzibah Rani S.;Carroll, Kevin F. Staveley-O';Irby, Rosalyn B.;Sharma, Arun K.;Amin, Shantu
通讯作者：
Amin, Shantu

The Akt inhibitor ISC-4 activates prostate apoptosis response protein-4 and reduces colon tumor growth in a nude mouse model.

DOI：
10.1158/1078-0432.ccr-10-2370
发表时间：
2011-07-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
0
作者：
Sharma AK;Kline CL;Berg A;Amin S;Irby RB
通讯作者：
Irby RB

The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer.